All In Biotech

Drug Trial Radar · NCT04684147

Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase Ⅱ Clinical Trial of CNCT19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Last checked: Nov 19, 2026Latest source record: Aug 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Dec 24, 2020

Primary completion

Sep 22, 2022

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Juventas Cell Therapy Ltd.Industry
Sponsor type
Industry
First posted
Dec 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute lymphoblastic leukemia.

Conditions

  • Relapsed or Refractory Acute Lymphoblastic Leukemia

Interventions

  • single dose of CNCT19Biological

    Dose: 0.5 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Remission Rate (ORR), which includes Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi) as determined by Independent Review Committee (IRC).Time frame: At 3 months after infusion

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Boren Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Xinqiao Hospital of TMMU

    Chongqing, Chongqing Municipality, China · Recruiting

  • Nanfang Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Yanda hospital, Hebei medical university

    Sanhe, Hebei, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • The affiliated hospital of Xuzhou medical university

    Xuzhou, Jiangsu, China · Recruiting

  • Tongji Hospital of Tongji University

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital,Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Institute of Hematology & Blood Diseases Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University school of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.